Over the past 16 months, Chinese-domiciled biopharmaceutical companies have emerged as significant players in the global drug development landscape, participating…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biotechnology companies have emerged as significant players in the global pharmaceutical landscape, securing approximately…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
The majority of these high-value collaborations, roughly half, involved firms of U.S. origin, predominantly structured as mergers and acquisitions (M&A).…
Read More
Chinese Biotechs Emerge as Global Pharma Powerhouses, Securing One-Third of Major Deal Value in 16 Months
Over the past sixteen months, Chinese-domiciled biotechnology companies have solidified their position as pivotal players in the global pharmaceutical landscape,…
Read More
Chinese Firms Landed 6 of 26 Major Pharma Deals in 16 Months, Worth $53 Billion
Over the past 16 months, Chinese-domiciled biopharmaceutical companies have emerged as formidable players in the global drug development landscape, securing…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biotechnology companies have emerged as formidable forces in the global pharmaceutical landscape, featuring prominently…
Read More
